Connect with us

Hi, what are you looking for?

Share Market

Divi’s Laboratories rating – Buy: Another strong quarter for the company

Financial Express - Business News, Stock Market News

Ebitda margin expanded by 278bp y-o-y and 296bp q-o-q, at 43.7%. PAT grew 12.1% y-o-y and 13.1% q-o-q, to Rs 5.5 bn.Ebitda margin expanded by 278bp y-o-y and 296bp q-o-q, at 43.7%. PAT grew 12.1% y-o-y and 13.1% q-o-q, to Rs 5.5 bn.

Revenue grew 14% y-o-y and 13.5% q-o-q in Q1 on a standalone basis, to Rs 19.5 bn, largely in line with expectations. The sales mix between the generics and custom synthesis segments was 50:50 (vs 60:40 in Q4). Carotenoids (part of generics) revenue was flat y-o-y and fell 11.5% q-o-q, to Rs 1.4 bn. Sales mix is a function of multiple factors and lower generics sales in Q1 does not indicate any slowdown for its outlook, per Divi’s.

The healthy 67% gross margin (+420bp y-o-y, -104bp q-o-q) was within the 67-69% range seen over the last few quarters. Mgmt credited its efforts over last few years in debottlenecking, backward integration, procurement efficiencies, adoption of efficient technologies, etc. Ebitda margin expanded by 278bp y-o-y and 296bp q-o-q, at 43.7%. PAT grew 12.1% y-o-y and 13.1% q-o-q, to Rs 5.5 bn.

Good visibility on growth drivers: Divi’s detailed the growth engines that support its long-term outlook: (a) established generics – the company commands a 60-70% global market share and sees headroom in market demand (market is growing at c10% p.a.); (b) other generics – Divi’s is aiming for a 60-70% market share (vs 20-30% now); (c) sartans – its “nitrosamine” impurity-free process with high level of backward integration should expand sartan sales; (d) contrast media – here the market is huge and Divi’s is in the process of signing up customer deals; (e) new generics – it is working on new generics where the global market is c$20 bn; and (f) two new custom synthesis projects with order visibility for the next few years.

Divi’s has invested significantly in these growth engines, and its cash balance of cRs 21 bn supports its capex needs. Molnupiravir (Merck’s oral COVID-19 drug in Phase 3 trial) could be a sizeable near-term opportunity, potentially adding c8% upside to our base-case FY22e revenue.

Retain Buy: We continue to like Divi’s visibility on growth drivers, and its proven execution on cost efficiencies. Pick-up in supply from added brownfield capacities to the regulated markets, progress in growth engines, and contribution from fast-tracked CS projects should support high-teens revenue growth in FY22-24e with healthy Ebitda margins of 40%+. Post Q1, we increase FY22-24e EPS by 2-5%, and our revised TP is Rs 5,465 (from Rs 5,130).

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like


Cybercriminals Adopt the Blockchain to Broadcast confidential Messages A group of analysts from SophosLabs represents that programmers working the crypto-jacking malware, Glupteba, have been...


PUBG unban in India soon as PUBG Corp. Will The Government Of India Unban PUBG? PUBG Mobile was Ban in India, PUBG organization has...


A standard method to execute Bitcoin could be powerless against double-spending, the new examination has found. Blockchain sleuths at ZenGo, a wallet startup, have...

BlockChain News

HDD mining, also known as “storage mining”, is a process of obtaining cryptocurrency based on hard disk memory. Compared with traditional POW mining, hard...